Skip to main content

Table 1 Patient recruitment

From: Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

Inclusion criteria
 1. Adults (>18 years) capable of providing informed consent with metastatic renal cell cancer
 2. Eastern cooperative oncology group (ECOG) performance status ≤ 2
Exclusion criteria
 1. Estimated prognosis < 12 weeks
 2. Contraindications to contrast enhanced CT, MRI or FDG/PET
 3. Women who are pregnant or lactating